ライフサイエンスコーパス: irritable bowel

1 a significant risk factor for postinfectious irritable bowel and chronic fatigue syndromes.

2 ructive pathologies of the two main forms of irritable bowel disease (IBD), ulcerative colitis (UC),

3 individuals, and those with colon cancer and irritable bowel disease (IBD), we demonstrated that CD4C

4 rylation was observed in colonic mucosa from irritable bowel disease patients.

5 tive protease pathway in the pathogenesis of irritable bowel disease.

6 centage of individuals with gastrointestinal/irritable bowel disease.

7 d may offer a therapeutic avenue in treating irritable bowel disease.

8 n who do not fit a specific disorder such as irritable bowel, functional dyspepsia, or abdominal migr

9 The prevalences of irritable bowel syndrome (39.4%) by Rome III criteria an

10 ), 6.78% in Crohn's disease (4/59), 5.82% in irritable bowel syndrome (51/877), and 4.9% in the remai

11 valences (per 100 residents) were stable for irritable bowel syndrome (8.3% and 11.4%, respectively)

12 subjects (aged 24-61 y, 6 men) with NCGS and irritable bowel syndrome (based on Rome III criteria), b

13 ota of patients with constipated-predominant irritable bowel syndrome (C-IBS) displays chronic dysbio

14 (FC), Gastrointestinal Symptoms Rating Scale-Irritable Bowel Syndrome (GSRS-IBS) and Hospital Anxiety

15 he Gastrointestinal Symptom Rating Scale for Irritable Bowel Syndrome (GSRS-IBS) into German and to e

16 red by Gastrointestinal Symptom Rating Scale Irritable Bowel Syndrome (GSRS-IBS) version.

17 also collected from 151 patients with CD or irritable bowel syndrome (IBS) (controls).

18 ed by the intestinal mucosa of patients with irritable bowel syndrome (IBS) affect the function of en

19 Irritable bowel syndrome (IBS) affects 7% to 21% of the

20 tudies have shown an increased prevalence of irritable bowel syndrome (IBS) after acute gastroenterit

21 patients (63.8%) had a previous diagnosis of irritable bowel syndrome (IBS) and 23 (28.8%) had one of

22 es from patients of colorectal cancer (CRC), irritable bowel syndrome (IBS) and controls to be run th

23 We investigated the role of TRPV1 in irritable bowel syndrome (IBS) and evaluated if an antag

24 symptoms, which occasionally mimic those of Irritable Bowel Syndrome (IBS) and Fibromyalgia Syndrome

25 hypnotherapy (HT) is effective in pediatric irritable bowel syndrome (IBS) and functional abdominal

26 tious gastroenteritis increases the risk for irritable bowel syndrome (IBS) and functional dyspepsia

27 ists are effective in treating patients with irritable bowel syndrome (IBS) and have anxiolytic effec

28 Irritable bowel syndrome (IBS) and inflammatory bowel di

29 Abuse history is common in irritable bowel syndrome (IBS) and is associated with gr

30 Very few studies report on the prevalence of irritable bowel syndrome (IBS) and its correlates in the

31 Women have a higher prevalence of irritable bowel syndrome (IBS) and possible differences

32 nning to shape a pathophysiological model of irritable bowel syndrome (IBS) and related functional ga

33 cally divergent, ulcerative colitis (UC) and irritable bowel syndrome (IBS) are both associated with

34 isease (GERD), functional dyspepsia (FD) and irritable bowel syndrome (IBS) are common functional gas

35 healthy children and pediatric patients with irritable bowel syndrome (IBS) are not well defined.

36 Approximately 1 in ten patients with irritable bowel syndrome (IBS) believe their IBS began w

37 cture is used by patients as a treatment for irritable bowel syndrome (IBS) but the evidence on effec

38 pathophysiology, diagnosis, and treatment of irritable bowel syndrome (IBS) convened to audit the cur

39 elationship between giardiasis diagnosis and irritable bowel syndrome (IBS) diagnosis.

40 suggestive of functional dyspepsia (FD) and irritable bowel syndrome (IBS) frequently overlap with t

41 unctional gastrointestinal disorders such as irritable bowel syndrome (IBS) has shifted fundamentally

42 Patients with irritable bowel syndrome (IBS) have high surgical rates.

43 Only a fraction of patients with irritable bowel syndrome (IBS) have increased perceptual

44 Patients with irritable bowel syndrome (IBS) have increased postprandi

45 odify pain end points in clinical trials for irritable bowel syndrome (IBS) highlights the knowledge

46 care consumption for patients diagnosed with Irritable Bowel Syndrome (IBS) in primary and secondary

47 Irritable bowel syndrome (IBS) is a chronic functional g

48 Irritable Bowel Syndrome (IBS) is a chronic/common condi

49 Irritable Bowel Syndrome (IBS) is a common condition cha

50 Irritable bowel syndrome (IBS) is a common functional ga

51 Irritable bowel syndrome (IBS) is a common gastrointesti

52 Irritable bowel syndrome (IBS) is a common gastrointesti

53 Irritable Bowel Syndrome (IBS) is a functional somatic s

54 Irritable bowel syndrome (IBS) is a gut-brain disorder i

55 Irritable bowel syndrome (IBS) is among the most common

56 BACKGROUND & AIMS: Irritable bowel syndrome (IBS) is associated with intest

57 Irritable bowel syndrome (IBS) is characterized by alter

58 Irritable bowel syndrome (IBS) is more common in patient

59 Irritable bowel syndrome (IBS) is one of the most common

60 Irritable bowel syndrome (IBS) is subtyped as IBS with d

61 f psychosocial disturbances with more severe irritable bowel syndrome (IBS) is well recognized.

62 Patients with irritable bowel syndrome (IBS) often relate symptoms to

63 Patients with Irritable Bowel Syndrome (IBS) often relate their sympto

64 role of the microbiota in the development of irritable bowel syndrome (IBS) only recently has been co

65 ) signaling pathways have been implicated in irritable bowel syndrome (IBS) pathophysiology.

66 lay a role in central pain amplification and irritable bowel syndrome (IBS) pathophysiology.

67 HPA axis response to a visceral stressor in irritable bowel syndrome (IBS) patients and healthy cont

68 efore aversive pelvic visceral distention in irritable bowel syndrome (IBS) patients and their possib

69 Visceral hypersensitivity in irritable bowel syndrome (IBS) patients has been documen

70 Syndrome (FMS) is a frequent comorbidity in Irritable Bowel Syndrome (IBS) patients with a higher fu

71 This study investigated Irritable Bowel Syndrome (IBS) prevalence in a sample of

72 The diagnosis of irritable bowel syndrome (IBS) relies on symptom-based c

73 Irritable bowel syndrome (IBS) remains an incompletely u

74 The pathophysiology of irritable bowel syndrome (IBS) remains enigmatic; abnorm

75 ll but significant subgroup of patients with irritable bowel syndrome (IBS) report a sudden onset of

76 Patients with irritable bowel syndrome (IBS) seen by a gastroenterolog

77 sorbed fermentable carbohydrates can provoke irritable bowel syndrome (IBS) symptoms by escaping abso

78 acy of psychological treatments for reducing irritable bowel syndrome (IBS) symptoms, the mechanisms

79 suspected food intolerances in patients with irritable bowel syndrome (IBS) using confocal laser endo

80 entable carbohydrates may induce symptoms of irritable bowel syndrome (IBS) via unclear mechanisms.

81 entable carbohydrates may induce symptoms of irritable bowel syndrome (IBS) via unclear mechanisms.

82 ept study for the treatment of patients with irritable bowel syndrome (IBS) with constipation (IBS-C)

83 st, which has been approved for treatment of irritable bowel syndrome (IBS) with constipation in wome

84 ciated with colonic transit in patients with irritable bowel syndrome (IBS) with diarrhea.

85 treatments are needed for patients who have irritable bowel syndrome (IBS) with diarrhea.

86 showed the benefit of a 5HT(3) antagonist in irritable bowel syndrome (IBS) with diarrhoea (IBS-D) an

87 of PI sequelae among exposed was as follows: irritable bowel syndrome (IBS), 3.0; dyspepsia, 1.8; con

88 and male healthy subjects and patients with irritable bowel syndrome (IBS), a common chronic abdomin

89 ve been implicated in the pathophysiology of irritable bowel syndrome (IBS), a visceral pain syndrome

90 the most bothersome symptom by patients with irritable bowel syndrome (IBS), and actual distention ma

91 including inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), and chronic constipation

92 s are abnormal in the ileum of patients with irritable bowel syndrome (IBS), and whether any abnormal

93 d genetic factors contribute to variation in irritable bowel syndrome (IBS), anxiety and depression.

94 ND & AIMS: Probiotics can reduce symptoms of irritable bowel syndrome (IBS), but little is known abou

95 ssants are effective in patients with severe irritable bowel syndrome (IBS), but the cost-effectivene

96 f these genetic variations with subgroups of irritable bowel syndrome (IBS), functional abdominal pai

97 Irritable bowel syndrome (IBS), functional bloating, fun

98 iated with three other functional disorders; irritable bowel syndrome (IBS), functional dyspepsia (FD

99 the area of functional GI syndromes such as irritable bowel syndrome (IBS), functional dyspepsia, an

100 ose was to evaluate the overlap frequency of irritable bowel syndrome (IBS), gastroesophageal reflux

101 In patients with irritable bowel syndrome (IBS), pain amplification and h

102 Irritable bowel syndrome (IBS), which affects 11% to 14%

103 In irritable bowel syndrome (IBS), which is the most common

104 l gastrointestinal symptoms in patients with irritable bowel syndrome (IBS), yet there is limited evi

105 testinal microbiota and clinical features of irritable bowel syndrome (IBS).

106 pulation each year, and is a risk factor for irritable bowel syndrome (IBS).

107 have important roles in the pathogenesis of irritable bowel syndrome (IBS).

108 the pathophysiology of anxiety disorders and irritable bowel syndrome (IBS).

109 studies of existing diagnostic criteria for irritable bowel syndrome (IBS).

110 microbiota might also play a similar role in irritable bowel syndrome (IBS).

111 relieve symptoms for patients suffering from irritable bowel syndrome (IBS).

112 versus usual care alone for the treatment of Irritable Bowel Syndrome (IBS).

113 important role in the pathophysiology of the irritable bowel syndrome (IBS).

114 used to treat patients with nonconstipating irritable bowel syndrome (IBS).

115 l nervous system is altered in patients with irritable bowel syndrome (IBS).

116 measure patient-reported outcomes (PROs) in irritable bowel syndrome (IBS).

117 the progression and evaluate the severity of irritable bowel syndrome (IBS).

118 he development of drugs for the treatment of irritable bowel syndrome (IBS).

119 nities to develop new therapeutic agents for irritable bowel syndrome (IBS).

120 y be important in the pathophysiology of the irritable bowel syndrome (IBS).

121 Visceral hypersensitivity is one feature of irritable bowel syndrome (IBS).

122 n of 5-HT is involved in the pathogenesis of irritable bowel syndrome (IBS).

123 er-related differences in FGID, particularly irritable bowel syndrome (IBS).

124 ted to reduce symptoms in some patients with irritable bowel syndrome (IBS).

125 ociated with abdominal pain in patients with irritable bowel syndrome (IBS).

126 testinal microbiota and clinical features of irritable bowel syndrome (IBS).

127 sing diet in the management of patients with irritable bowel syndrome (IBS).

128 effective in the treatment of patients with irritable bowel syndrome (IBS).

129 agonists might be involved in development of irritable bowel syndrome (IBS).

130 by mutations in SCN5A also have symptoms of irritable bowel syndrome (IBS).

131 in, constipation, and bloating; diagnoses of irritable bowel syndrome (IBS); and tegaserod prescripti

132 alence of celiac disease among patients with irritable bowel syndrome (IBS); few data are available w

133 fies the FBDs into five distinct categories: irritable bowel syndrome (IBS); functional constipation

134 and polyols (FODMAPs) exacerbate symptoms of irritable bowel syndrome (IBS); however, their mechanism

135 red an important pathophysiologic symptom in irritable bowel syndrome (IBS); previous gastrointestina

136 compared to a milk product in subjects with irritable bowel syndrome (IBS, n = 28).

137 in the treatment of constipation predominant irritable bowel syndrome (IBS-C), a highly prevalent dis

138 ogenetics of CDC in constipation-predominant irritable bowel syndrome (IBS-C).

139 Patients with diarrhea-predominant irritable bowel syndrome (IBS-D) could benefit from a gl

140 Some patients with diarrhea-predominant irritable bowel syndrome (IBS-D) may have undiagnosed ce

141 ned diarrhea, including diarrhea-predominant irritable bowel syndrome (IBS-D).

142 efficacy and safety for diarrhea-predominant irritable bowel syndrome (IBS-D).

143 ouse model that reproduces major features of irritable bowel syndrome (long-lasting colon hypersensit

144 hat patients with symptoms of nonconstipated irritable bowel syndrome (NC-IBS) undergo testing for ce

145 04-1.1), diarrhea (OR, 53; 95% CI, 6.1-471), irritable bowel syndrome (OR, 4.8; 95% CI, 1.6-14), chol

146 Post-infectious irritable bowel syndrome (PI-IBS) is a common gastrointe

147 he role of gut microbiota in post-infectious irritable bowel syndrome (PI-IBS) is convincing.

148 ith increased rate ratios (RRs) for incident irritable bowel syndrome (RR, 6.1; 95% confidence interv

149 o an online database called Transcriptome of Irritable Bowel Syndrome (TIBS).

150 Of them, 305 (16.5%) had AP-FGD [irritable bowel syndrome = 91(4.9%), functional dyspepsi

151 who are in remission and those who developed irritable bowel syndrome after enteric infection continu

152 in the treatment of constipation-predominant irritable bowel syndrome and chronic constipation.

153 ate the persistence, prevalence, and risk of irritable bowel syndrome and chronic fatigue 6 years aft

154 ing is associated with an increased risk for irritable bowel syndrome and chronic fatigue 6 years lat

155 Clinical studies show that patients with irritable bowel syndrome and colonic diseases frequently

156 Although symptomatic irritable bowel syndrome and Crohn's disease patients ha

157 nic gastrointestinal diseases-liver disease, irritable bowel syndrome and dyspepsia, and inflammatory

158 associated with diarrheal conditions such as irritable bowel syndrome and enteric infections.

159 gastrointestinal tract disorders, including irritable bowel syndrome and gastroesophageal reflux dis

160 with postinfectious complications, including irritable bowel syndrome and Guillain-Barre syndrome.

161 ter, are at increased risk of postinfectious irritable bowel syndrome and inflammatory bowel disease

162 Colon disorders, including irritable bowel syndrome and inflammatory bowel disease,

163 sit and gut microbial communities, including irritable bowel syndrome and inflammatory bowel disease.

164 long-term effects, including postinfectious irritable bowel syndrome and inflammatory bowel disease.

165 ensal gut flora in such common conditions as irritable bowel syndrome and inflammatory bowel disease.

166 Both irritable bowel syndrome and inflammatory bowel diseases

167 , appeared to be most genetically similar to irritable bowel syndrome and most environmentally simila

168 stion that SIBO may be a causative factor in irritable bowel syndrome and of its constituent symptoms

169 successfully treat constipation-predominant irritable bowel syndrome and recent studies show that ex

170 (EPI) confound interpretation of findings in irritable bowel syndrome and severe renal insufficiency.

171 al gastrointestinal disorders, most commonly irritable bowel syndrome but also other functional and o

172 nalities with inflammatory bowel disease and irritable bowel syndrome but were focused on associative

173 ely prescribing antibiotics to patients with irritable bowel syndrome can be endorsed.

174 This activation may have relevance to irritable bowel syndrome characterized by lower pain thr

175 in small intestinal bacterial overgrowth in irritable bowel syndrome continues, the utility and spec

176 While interest in bacterial overgrowth in irritable bowel syndrome continues, the utility and spec

177 In the exposed group, the prevalence of irritable bowel syndrome decreased by 6.7% (RR, 0.85 [95

178 The peripheral component is prominent in irritable bowel syndrome developing after infection (pos

179 ease in IBD risk for persons with a previous irritable bowel syndrome diagnosis.

180 opsies were also taken from 16 patients with irritable bowel syndrome diarrhea who comprised the cont

181 antibiotics and concurrently, postinfectious irritable bowel syndrome has been associated with a long

182 Traditionally, irritable bowel syndrome has been considered to be a dis

183 Irritable bowel syndrome has been referred to as a funct

184 The study of post-infectious irritable bowel syndrome has revealed the importance of

185 treatment options for diarrhoea-predominant irritable bowel syndrome have had not very promising res

186 valuate the effectiveness of acupuncture for irritable bowel syndrome in primary care when provided a

187 ment of the diarrhea-predominant form of the irritable bowel syndrome in women suggests the importanc

188 Underlying mechanisms that could lead to irritable bowel syndrome include genetic factors (most n

189 It has suggested novel approaches to irritable bowel syndrome including studies of serotonin

190 w we challenge the widely accepted view that irritable bowel syndrome is an unexplained brain-gut dis

191 Irritable bowel syndrome is characterized by altered sen

192 ecent studies have overthrown the dogma that irritable bowel syndrome is characterized by no abnormal

193 Irritable bowel syndrome is classified as a functional g

194 toms and the strong overlap between GERD and irritable bowel syndrome is due to the influence of NERD

195 noxious stimulation in the context of human irritable bowel syndrome is questionable.

196 interventions are enjoying a renaissance in irritable bowel syndrome management.

197 Postinfectious irritable bowel syndrome may occur in 3% to 17% of patie

198 orphic nature of some pelvic diseases, e.g., irritable bowel syndrome or cystitis.

199 Irritable bowel syndrome patients form a heterogeneous g

200 een the control group and Crohn's disease or irritable bowel syndrome patients in terms Blastocystis

201 ersensitivity of primary afferent neurons in irritable bowel syndrome patients.

202 Acupuncture for irritable bowel syndrome provided an additional benefit

203 Irritable bowel syndrome refers to abdominal discomfort

204 Irritable bowel syndrome remains an incompletely underst

205 The role of bacterial overgrowth in irritable bowel syndrome requires further study.

206 Identical irritable bowel syndrome symptoms are probably due to di

207 ortance of low-grade inflammation in causing irritable bowel syndrome symptoms.

208 Noninflammatory irritable bowel syndrome was induced by intracolonic ins

209 233 patients with irritable bowel syndrome were randomly allocated to eith

210 n important clinical feature associated with irritable bowel syndrome which in some patients has been

211 ion, 15 with functional bloating, and 3 with irritable bowel syndrome with alternating bowel habits)

212 Irritable bowel syndrome with constipation (IBS-C) affec

213 Patients with irritable bowel syndrome with constipation (IBS-C) and p

214 GC-C) that reduces symptoms associated with irritable bowel syndrome with constipation (IBS-C).

215 C) includes functional constipation (FC) and irritable bowel syndrome with constipation (IBS-C).

216 ith functional intestinal disorders (27 with irritable bowel syndrome with constipation, 15 with func

217 ed by >2 symptoms of chronic constipation or irritable bowel syndrome with constipation, and with >2

218 tion subtypes of functional constipation and irritable bowel syndrome with constipation.

219 Some patients with irritable bowel syndrome with diarrhea (IBS-D) have inte

220 abdominal pain and diarrhea in patients with irritable bowel syndrome with diarrhea (IBS-D) without c

221 Chronic idiopathic constipation (CC) and irritable bowel syndrome with predominant constipation (

222 The term "irritable bowel syndrome" was used to search Clinical Ev

223 chronic fatigue syndrome' and 'Dopamine and irritable bowel syndrome' was carried out until April 20

224 tic syndromes', 'Chronic fatigue syndrome', 'Irritable bowel syndrome', 'Fibromyalgia', 'Dopamine and

225 developing after infection (post-infectious irritable bowel syndrome) and this has proved a profitab

226 rome, reactive arthritis, and postinfectious irritable bowel syndrome) contribute considerably to the

227 scribed (e.g. inflammatory bowel disease and irritable bowel syndrome).

228 e into the development of new approaches for irritable bowel syndrome, a multifactorial disorder for

229 ysiology, etiology, pathogenesis, diagnosis, irritable bowel syndrome, and IBS.

230 broid food poisoning, histamine intolerance, irritable bowel syndrome, and inflammatory bowel disease

231 These include inflammatory bowel diseases, irritable bowel syndrome, and metabolic (i.e. obesity, n

232 robiota, such as inflammatory bowel disease, irritable bowel syndrome, and metabolic syndrome, to nam

233 owel diseases, celiac disease, food allergy, irritable bowel syndrome, and--more recently recognized-

234 festations of celiac disease that include an irritable bowel syndrome, anemia, osteoporosis, neurolog

235 ders, such as inflammatory bowel disease and irritable bowel syndrome, are associated with exaggerate

236 disorders (cardiovascular disease, diabetes, irritable bowel syndrome, asthma, and others).

237 to human physiology and to diseases such as irritable bowel syndrome, autism, anxiety, depression, a

238 EC has been implicated in the development of irritable bowel syndrome, but this remains to be confirm

239 terpersonal therapy, and antidepressants for irritable bowel syndrome, chronic fatigue syndrome, and

240 , management, and role in conditions such as irritable bowel syndrome, chronic fatigue, and autoimmun

241 Chronic pain syndromes irritable bowel syndrome, chronic pelvic pain, and fibro

242 ur findings link duplications in TPSAB1 with irritable bowel syndrome, cutaneous complaints, connecti

243 expanded from 1946 to December 2014 for IBS, irritable bowel syndrome, diet, treatment, and therapy.

244 ted with chronic prostatitis/CPPS, including irritable bowel syndrome, fibromyalgia, and chronic fati

245 r directly co-morbid somatic disorders, e.g. irritable bowel syndrome, fibromyalgia, or migraine.

246 This issue provides a clinical overview of irritable bowel syndrome, focusing on diagnosis, treatme

247 d in the setting of differentiating IBD from irritable bowel syndrome, for grading inflammation, to d

248 nter placebo-controlled trial, children with irritable bowel syndrome, functional abdominal pain, or

249 female patients with moderate to severe FBD (irritable bowel syndrome, functional abdominal pain, pai

250 mechanisms may predispose the individual to irritable bowel syndrome, gastroesophageal reflux diseas

251 orders including inflammatory bowel disease, irritable bowel syndrome, infectious and antibiotic-asso

252 ith active UC, inactive UC, Crohn's disease, irritable bowel syndrome, infectious colitis, and micros

253 ute pancreatitis, bacterial gastroenteritis, irritable bowel syndrome, inflammatory bowel disease, he

254 nfection, small bowel intestinal overgrowth, irritable bowel syndrome, inflammatory bowel disease, po

255 , including Clostridium difficile infection, irritable bowel syndrome, inflammatory bowel diseases, i

256 Irritable bowel syndrome, interstitial cystitis, and oth

257 and of patients with the common symptoms of irritable bowel syndrome, iron deficiency anemia, unexpl

258 In women with constipation-predominant irritable bowel syndrome, linaclotide 1000 microg once d

259 fibromyalgia, generalized anxiety disorder, irritable bowel syndrome, migraine, obsessive-compulsive

260 hea and colitis, inflammatory bowel disease, irritable bowel syndrome, necrotizing enterocolitis, and

261 vergrowth is one of the causes suggested for irritable bowel syndrome, particularly for the diarrhoea

262 mens from patients with UC, Crohn's disease, irritable bowel syndrome, sporadic colorectal cancer, or

263 ents meeting current diagnostic criteria for irritable bowel syndrome, therapeutic approaches shown t

264 liaison psychiatric setting in patients with irritable bowel syndrome, where positive benefits have b

265 Irritable bowel syndrome, which affects 5-10% of the pop

266 ctional bowel disorders (FBDs), particularly irritable bowel syndrome, with the objective of elucidat

267 abdominal pain experienced by patients with irritable bowel syndrome, yet the molecules that confer

268 est drug to be approved for the treatment of irritable bowel syndrome-diarrhoea is rifaximin, which w

269 findings, are nonspecific, and can simulate irritable bowel syndrome.

270 es such as fibromyalgia, chronic fatigue and irritable bowel syndrome.

271 cupuncture is a cost-effective treatment for irritable bowel syndrome.

272 osed inflammatory bowel disease and 877 with irritable bowel syndrome.

273 be cost-effective for those with more severe irritable bowel syndrome.

274 other involving children suffering from the irritable bowel syndrome.

275 tion between infection with Blastocystis and irritable bowel syndrome.

276 rted polymorphisms in the pathophysiology of irritable bowel syndrome.

277 e clearly established a genetic component in irritable bowel syndrome.

278 abdominal pain and cramping in patients with irritable bowel syndrome.

279 tem, such as chemotherapy-induced emesis and irritable bowel syndrome.

280 ntirely functional, such as in some cases of irritable bowel syndrome.

281 s may have a role in nondiarrhea predominant irritable bowel syndrome.

282 - have developing roles in the treatment of irritable bowel syndrome.

283 overgrowth may be important for treatment of irritable bowel syndrome.

284 in is effective in preventing postinfectious irritable bowel syndrome.

285 ntary and alternative medicine therapies for irritable bowel syndrome.

286 eral hypersensitivity is a characteristic of irritable bowel syndrome.

287 possible therapies for certain patients with irritable bowel syndrome.

288 h mucosa and blood have been demonstrated in irritable bowel syndrome.

289 ses substantial morbidity and postinfectious irritable bowel syndrome.

290 Patients often have a previous diagnosis of irritable bowel syndrome.

291 ations in sensory processing associated with irritable bowel syndrome.

292 disorder, multiple chemical sensitivity, and irritable bowel syndrome.

293 ultimately provide a cure for patients with irritable bowel syndrome.

294 NR1) have been associated with some forms of irritable bowel syndrome.

295 ergrowth participates in the pathogenesis of irritable bowel syndrome.

296 hanced toxin sensitivity in a mouse model of irritable bowel syndrome.

297 psy, ataxia, pain, arrhythmia, myotonia, and irritable bowel syndrome.

298 y, in 36 women with constipation-predominant irritable bowel syndrome; colonic transit was normal in

299 ed to control (P<.001) and disease controls (irritable bowel syndrome; P<.001; rheumatoid arthritis;

300 searched by using medical subject headings ("irritable bowel syndrome;" "colonic diseases, functional